DDInter416 DDInter997
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Clotrimazole {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Clotrimazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Clotrimazole {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) resembles {v} (Compound) Darifenacin
Darifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Diphenidol {u} (Compound) resembles {v} (Compound) Bepridil
Bepridil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Clotrimazole (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Ivacaftor (Compound)
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Clotrimazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Clotrimazole (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Darifenacin (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Clotrimazole (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Bepridil (Compound) and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)